Cerus Corporation Announces Schedule of Presentations at the AABB 2020 Virtual Annual Meeting
September 28 2020 - 8:30AM
Business Wire
Cerus Corporation (Nasdaq:CERS) announced today its lineup of
abstract presentations at the AABB 2020 Virtual Annual Meeting,
which will take place on October 3rd through October 5th.
This year’s Virtual Annual Meeting remains one of the largest
scientific symposiums focused on the field of transfusion medicine.
Scientists and clinicians from around the globe will share the
latest research and practice-changing resources in the fields of
blood and biotherapies. Highlights from this year’s agenda include
COVID-19-related research, and insights from AABB’s Standards
Committee chairs on the new and revised standards and guidances
impacting global blood safety.
“This is a hallmark event for Cerus and we look forward to
connecting with our colleagues in the global transfusion medicine
community,” said Dr. Richard Benjamin, Cerus’ chief medical
officer. “Despite being virtual due to COVID-19, we are excited to
present the latest clinical data supporting the use of
INTERCEPT-treated blood components from Cerus and our scientific
collaborators. This year, we will have 17 abstracts, including one
oral presentation,” Benjamin continued.
“With the FDA Guidance for Industry on Bacterial Risk Control
Strategies for Platelets six months away (March 31, 2021), Cerus
will present several abstracts on this topic, including one focused
on the economic aspects of INTERCEPT implementation in blood
centers and hospitals,” Benjamin said. “As we near this important
milestone in the U.S., we are focused on providing the data most
valuable to the transfusion community,” he continued.
Currently, the major blood centers in the U.S. are moving ahead
with broad roll-out of the INTERCEPT Blood System to meet the
guidance.
A full list of abstracts from Cerus is available to view at:
https://intercept-usa.com/aabb2020
The Cerus oral presentation, entitled, “Optimizing U.S.
Platelet Supply by Shifting Minimum Platelet Dose” will be
presented on October 3rd at 7:15 p.m./EST.
Excerpts from select Cerus abstracts this year
include:
- Optimizing US Platelet Supply by Shifting Minimum Platelet
Dose, Travis Berry, Meredith Lummer The inclusion of lower
minimum dose platelet products enables blood centers to increase
platelet component availability while implementing FDA Bacterial
Guidance strategies.
- Optimizing Platelet Availability and Access to a ~100%
Pathogen Reduced Inventory, Tracy Collier, Vera Chrebtow,
Patricia Schmidt A blood center’s experience with decreased
platelet expiry resulting in $120,000 in savings per year when
converting to a 100% pathogen reduced platelet inventory.
- Costs and Reimbursements for Bacterial Risk Control
Strategies for Platelets: Results from a Hospital Budget Impact
Model, Katherine M. Prioli, Jay H. Herman, Laura T. Pizzi
Comparable net budget impact is shown between pathogen reduced and
large volume delayed sample tested platelet products with a
hospital budget impact model.
- In Vitro Evaluation of Platelets Stored for 7 Days Prepared
with INTERCEPT Blood System, Jamie R. Genthe, Waseem Anani,
Jose A. Cancelas, et al. In vitro study demonstrates retained
metabolic and functional properties of INTERCEPT-treated platelet
components stored for 7 days. (The INTERCEPT Blood System for 7-day
storage of platelets is not approved in the US. Clinical trials are
in progress: ClinicalTrials.gov Identifier: NCT04022889.)
- Efficient Inactivation of SARS-CoV-2 in Human Plasma with
Amotosalen and Ultraviolet A Light Treatment, Esam I. Azhar,
Salwa I. Hindawi, et al. Complete inactivation of SARS-CoV-2 was
observed with INTERCEPT treatment of spiked plasma units. INTERCEPT
may be effective in minimizing transfusion-transmitted infections
of SARS-CoV-2.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the
world’s blood supply and aims to become the preeminent global blood
products company. Based in Concord, California, our employees are
dedicated to deploying and supplying vital technologies and
pathogen-protected blood components for blood centers, hospitals
and ultimately patients who rely on safe blood. With the INTERCEPT
Blood System, we are focused on protecting patients by delivering
the full complement of reliable products and expertise for
transfusion medicine. Cerus develops and markets the INTERCEPT
Blood System and remains the only company in the blood transfusion
space to earn both CE Mark and FDA approval for pathogen reduction
of both platelet and plasma components. Cerus currently markets and
sells the INTERCEPT Blood System in the United States, Europe, the
Commonwealth of Independent States, the Middle East and selected
countries in other regions around the world. The INTERCEPT Red
Blood Cell system is in clinical development. For more information
about Cerus, visit www.cerus.com and follow us on LinkedIn.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus
Corporation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200928005223/en/
Tim Lee – Investor Relations Director Cerus Corporation
925-288-6137
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cerus (NASDAQ:CERS)
Historical Stock Chart
From Sep 2023 to Sep 2024